
|Articles|August 27, 2008
FDA speeds up review of Droxidopa
The drug is marketed in Japan to treat low blood pressure.
Advertisement
The Food and Drug Administration has given fast-track designation to Droxidopa, which is marketed in Japan to treat low blood pressure. Such a designation is reserved for drugs that treat serious conditions for which there is an unmet need. The maker of the drug, Chelsea Therapeutics International, says it plans to seek marketing approval for Droxidopa after completing clinical trials this year.
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Study Identifies Patients at Risk for Severe COVID-19 Post-Vaccination
2
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
3
Investigational Oral AD109 Reduces Sleep Apnea Severity by 44%
4
Zepbound Lowers Health Care Costs in Older Adults With Obesity
5






































